Company intelligence / Profile preview
elbion
Radebeul, Saxony, Germany
- Ownership
- Private
- Development stage
- Other
01
Overview
elbion developed a pipeline of small molecule drugs for CNS and immunological diseases. Lead assets included Naltrexone Depot for alcohol dependence (approaching Phase III), ELB245 for overactive bladder (Phase II), ELB353 as a PDE4 inhibitor for chronic inflammation (Phase I), and AWD 12–281 as a topical PDE4 inhibitor for atopic dermatitis partnered with GSK. The company also had research collaborations with major pharma companies such as Wyeth and Gilead Sciences
- Therapeutic areas
- ImmunologyNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Wyeth(phosphodiesterase10 program )Lundbeck(Nalmefene ,via parent Biotie )Gilead Sciences(HCV research collaboration )Roche(collaboration partner via parent post-merger )GlaxoSmithKline(AWD12 –281 partnership )
Beyond the preview
Go deeper on elbion.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on elbion.